St. Louis, Missouri - September 27, 2010 

Reliable Biopharmaceutical Corporation ("RBC") today announced that David Feldker will join RBC and become its CEO and President effective October 23, 2010, and join RBC's Board of Directors.  David was previously Vice President SAFC at Sigma-Aldrich Corp. with responsibility for the Active Pharmaceutical Ingredient ("API") contract development and manufacturing segment.

"David built SAFC Pharma into one of the leading developers and manufacturers of High Potency APIs and Biologic Ingredients" said RBC Chairman of the Board James A. Breckenridge.  "As RBC continues to grow, David is the perfect executive to lead RBC and capitalize on its complex chemistry capabilities, strong customer relationships as well as its robust API pipeline for generic injectable drugs."  

"RBC has built an excellent reputation around high purity ingredients and active pharmaceutical ingredients" said Feldker.  "The company has accomplished a great deal over the past few years and I look forward to working together to take it to the next level." 

"We are excited about David joining our team" said Vicente Trelles, co-founding partner of Med Opportunity Partners, LLC.  "David is an outstanding executive and his experience and leadership in managing a multimillion dollar business will be key to RBC's success."

Mike Zaleski will be stepping down as RBC's President and CEO effective October 22, 2010 but remain an advisor to the RBC Board of Directors during the transition.

About Reliable Biopharmaceutical Corporation

Founded in 1968, RBC is an integrated developer and manufacturer of active pharmaceutical ingredients ("APIs") and High Purity Ingredients ("HPIs") for pharmaceuticals and biologics.  RBC has established a strong position as a leading developer and manufacturer of complex generic injectable APIs.  The Company has developed 18 generic injectable APIs to date that have been approved as Type II Drug Master Files by the FDA and has 14 more in various stages of development.  RBC's products are the active ingredients for leading generic injectable drugs that treat cancer, heart disease, hypertension, anxiety and other serious and life threatening illnesses.  RBC also manufactures critical processing aids for the pharmaceutical industry and currently supplies these products to many of the world's leading pharmaceutical and biotechnology companies. RBC is a portfolio company of Med Opportunity Partners, LLC.  

About Med Opportunity Partners, LLC 

Med Opportunity Partners, LLC (www.MedOpportunity.com) is a Greenwich, CT- based operating oriented private equity firm that acquires leading healthcare companies at their growth stage. MEDOP is dedicated to investing in companies that drive healthcare innovation, growth and consolidation.  Founded by seasoned healthcare operators and investors, MEDOP partners with companies that can benefit from its extensive industry knowledge, relationships and proven operating and transaction experience.  MEDOP receives funding from prominent investors including pension funds, endowments, insurance companies, and private families.   

For more information, contact: 

Med Opportunity Partners, LLC
James A. Breckenridge, Founding Member (203-622-1333)
Two Soundview Drive, Suite 100
Greenwich, CT  0683